BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Drug Development

  Tetra Discovery Partners Research Supports Ability of Novel Selective PDE4D Inhibitor, BPN14770, to Improve Memory and Cognition

  BPN14770 is a highly selective inhibitor of PDE4D, which regulates brain signaling pathways involved in the early and late stages of memory formation.

  November 6, 2017

   · 

  5 min read
• Drug Development

  Wave Life Sciences Initiates Clinical Trial for Lead Program in Duchenne Muscular Dystrophy

  This clinical trial marks the next stage in the company’s ongoing commitment to address the significant unmet needs of patients diagnosed with this devastating disease and it is the company’s third clinical trial initiated in 2017.

  November 6, 2017

   · 

  7 min read
• Business

  Translate Bio Appoints Ann Barbier, M.D., Ph.D., as Chief Medical Officer

  Translate Bio today announced the appointment of Ann Barbier, M.D., Ph.D., as chief medical officer, effective immediately.

  November 6, 2017

   · 

  2 min read
• Biotech Bay

  Natera Selected for Circulating Tumor DNA Study in Colorectal Cancer

  Natera today announced a second research collaboration with Denmark’s Aarhus University utilizing the company’s Signatera technology to evaluate ctDNA as a useful biomarker for detecting minimal residual disease, treatment response, and disease recurrence in colorectal cancer patients.

  November 6, 2017

   · 

  5 min read
• BioMidwest

  Exicure Closes Additional $11.2 Million in Private Financing to Advance Its Gene Regulatory and Immunotherapeutic Programs

  Exicure today announced the closing of approximately $11.2 million in subsequent financing led by Luye Pharma Group and others including Eager Info Investments LTD, Knoll Capital Management and Purple Arch Ventures.

  November 6, 2017

   · 

  4 min read
• Biotech Beach

  ResMed Adds Remote Patient Monitoring to AirMini, World’s Smallest CPAP

  ResMed today announced that AirMini, the world’s smallest PAP device, is now connected to AirView, the world’s largest remote patient monitoring platform.

  November 6, 2017

   · 

  2 min read
• Business

  CytRx Announces Strategic Realignment of Clinical Development Team

  Going forward, CytRx’s drug development, manufacturing and regulatory activities will be led by Hurley Consulting Associates Ltd.

  November 6, 2017

   · 

  3 min read
• Drug Development

  UroGen Pharma Announces First Patient Enrolled in Allergan Phase II Clinical Trial of RTGel in Combination With BOTOX for the Treatment of Overactive Bladder

  The trial is being conducted by Allergan Pharmaceuticals International Limited, or Allergan, a wholly owned subsidiary of Allergan plc, under the terms of a license agreement with UroGen Pharma.

  November 6, 2017

   · 

  5 min read
• Drug Development

  Concert Pharmaceuticals Announces Completion of Enrollment in First Cohort of CTP-543 Phase IIa Trial

  The Phase 2a trial is expected to be completed in the second half of 2018.

  November 6, 2017

   · 

  5 min read
• Drug Development

  BriaCell Provides Clinical Update on its Lead Vaccine Candidate, BriaVax

  The Phase I/IIa study evaluates the safety and activity of BriaVax in patients with advanced breast cancer. To boost the anti-tumor effects of BriaVax.

  November 6, 2017

   · 

  6 min read